The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study
Abstract
Introduction: Autoimmunity against the TSH receptor is a key pathogenic element in Graves' disease. The autoimmune aberration may be modified by therapy of the hyperthyroidism. Objective: To compare the effects of the common types of therapy for Graves' hyperthyroidism on TSH-receptor autoimmunity. Methods: Patients with newly diagnosed Graves' hyperthyroidism aged 20–55 years were randomized to medical therapy, thyroid surgery, or radioiodine therapy (radioiodine was only given to patients ≥35 years of age). l -thyroxine ( l -T 4 ) was added to therapy as appropriate to keep patients euthyroid. Anti-thyroid drugs were withdrawn after 18 months of therapy. TSH-receptor antibodies (TRAb) in serum were measured before and for 5 years after the initiation of therapy. Results: Medical therapy ( n =48) and surgery ( n =47) were followed by a gradual decrease in TRAb in serum, with the disappearance of TRAb in 70–80% of the patients after 18 months. Radioiodine therapy ( n =36) led to a 1-year long worsening of autoimmunity against the TSH receptor, and the number of patients entering remission of TSH-receptor autoimmunity with the disappearance of TRAb from serum during the following years was considerably lower than with the other types of therapy. Conclusion: The majority of patients with Graves' disease gradually enter remission of TSH-receptor autoimmunity during medical or after surgical therapy, with no difference between the types of therapy. Remission of TSH-receptor autoimmunity after radioiodine therapy is less common.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the group with elevated TRAb, relapse rates approach 80%-100%, while in the latter group, relapse rates are in the 20%-30% range (171,172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“TRAb assessment at the end of the course of ATD therapy is a useful method of dividing patients into two groups: one with persistent elevations who are unlikely to be in remission, and another group with low or undetectable TRAb, who have a higher probability of permanent remission (171,172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“Whereas monitoring of TRAb levels while on ATDs has been shown to be useful in adult patients for predicting the likelihood of remission or relapse of GD after stopping the medication (172), this approach has yet to be validated in children.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“The higher risk of GO development after RAI therapy in the majority of studies may be related to the unique increase in TRAb levels observed following this therapy (172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
Citations
Cites
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Self-citationEpidemiology and Prevention of Graves' Ophthalmopathy
Wiersinga, W. M., & Bartalena, L. (2002) · Thyroid · doi:10.1089/105072502761016476 · Cited by 457
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
Gerding, M. N., Meer, J. W. C. V. D., Broenink, M., Bakker, O., Wiersinga, W. M., & Prummel, M. F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00959.x · Cited by 328
Törring, O., Tallstedt, L., Wallin, G., Lundell, G. E. F., Ljunggren, J. ‐., Taube, A., Sääf, M., & Hamberger, B. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768863 · Cited by 311
Self-citationCarbimazole and the Autoimmune Response in Graves' Disease
McGregor, A. M., Petersen, M. M., McLachlan, S. M., Rooke, P., Smith, B. R., & Hall, R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198008073030603 · Cited by 274
Thyrotropin receptor-associated diseases: from adenomata to Graves disease
Davies, T. F. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26031 · Cited by 260
Fatourechi, V. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506050-00003 · Cited by 207
LIPPE, B. M., LANDAW, E. M., & KAPLAN, S. A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-6-1241 · Cited by 192
Laurberg, P., Nygaard, B., Glinoer, D., Grussendorf, M., & Orgiazzi, J. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390584 · Cited by 191
Self-citation
Research works printed but not linked: 8
- 1992, New England Journal of Medicine, 25, 1733
- Torring, 1996, Journal of Clinical Endocrinology & Metabolism, 81, 2986, 10.1210/jc.81.8.2986 · DOI
- Smith, 2004, Thyroid : official journal of the American Thyroid Association, 14, 830, 10.1089/1050725042451248 · DOI
- 1980, New England Journal of Medicine, 7, 302
- Kung, 1994, Journal of Clinical Endocrinology & Metabolism, 79, 542, 10.1210/jc.79.2.542 · DOI
- 1998, New England Journal of Medicine, 8, 73
- 1979, JAMA, 30, 2408
- 2005, New England Journal of Medicine, 3, 905
Cited by
Sorted by citations
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
“In the majority of patients with GD, ATD therapy is followed by a gradual remission of disease with a possibility of disappearance of TRAb from circulation (172).”
BackgroundMethodInfluentialSelf-citationAlexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Self-citationBartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A. K., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,166
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Self-citation2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K. G., & Pearce, S. H. S. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 1,025
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Self-citationThyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases
Fröhlich, E., & Wahl, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00521 · Cited by 464
Thyroid disease in pregnancy: new insights in diagnosis and clinical management
Korevaar, T. I. M., Medici, M., Visser, T. J., & Peeters, R. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.93 · Cited by 441
Davies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro‐Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 421
Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
Bartalena, L., Piantanida, E., Gallo, D., Lai, A., & Tanda, M. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.615993 · Cited by 386
A 2011 Survey of Clinical Practice Patterns in the Management of Graves' Disease
Burch, H. B., Burman, K. D., & Cooper, D. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2802 · Cited by 346
Bonnema, S. J., & Hegedűs, L. D. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 340
Burch, H. B., & Cooper, D. S. (2015) · JAMA · doi:10.1001/jama.2015.16535 · Cited by 344
Lee, S. Y., & Pearce, E. N. (2023) · JAMA · doi:10.1001/jama.2023.19052 · Cited by 364
Diagnosis and management of Graves disease: a global overview
Bartalena, L. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.193 · Cited by 311
Extrathyroidal manifestations of Graves’ disease: a 2014 update
Bartalena, L., & Fatourechi, V. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0097-2 · Cited by 281
Träisk, F., Tallstedt, L., Abraham-Nordling, M., Andersson, T., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nyström, E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0747 · Cited by 262
Self-citationBreaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.
Mclachlan, S., & Rapoport, B. (2014) · Endocrine reviews · doi:10.1210/er.2013-1055 · Cited by 230
McLachlan, S. M., & Rapoport, B. (2013) · Thyroid · doi:10.1089/thy.2012.0374 · Cited by 239
Clinical Utility of TSH Receptor Antibodies
Barbesino, G., & Tomer, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4309 · Cited by 237
Management of Graves Thyroidal and Extrathyroidal Disease: An Update
Kahaly, G. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa646 · Cited by 237
Assessment and treatment of thyroid disorders in pregnancy and the postpartum period
Lee, S. Y., & Pearce, E. N. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00604-z · Cited by 236
Type 1 iodothyronine deiodinase in human physiology and disease
Maia, A. L., Goemann, I. M., Meyer, E. L. D. S., & Wajner, S. M. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0481 · Cited by 229
Current Insights into the Pathogenesis of Graves’ Ophthalmopathy
Bahn, R. S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555762 · Cited by 222
Current concepts regarding Graves’ orbitopathy
Bartalena, L., & Tanda, M. L. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13524 · Cited by 215
Graves' Ophthalmopathy: Epidemiology and Natural History
Hiromatsu, Y., Eguchi, H., Tani, J., Kasaoka, M., & Teshima, Y. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1518 · Cited by 193
Testicular adrenal rest tumours in congenital adrenal hyperplasia
Claahsen-van der Grinten, H. L., Otten, B. J., Stikkelbroeck, M. M. L., Sweep, F. C. G. J., & Hermus, A. R. M. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.007 · Cited by 187
Laurberg, P., Bournaud, C., Karmisholt, J., & Orgiazzi, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0663 · Cited by 178
Self-citationWiersinga, W. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0307 · Cited by 129
Chaker, L., Cooper, D. S., Walsh, J. P., & Peeters, R. P. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02016-0 · Cited by 143
Graves Hyperthyroidism and Pregnancy: A Clinical Update
Patil-Sisodia, K., & Mestman, J. H. (2009) · Endocrine Practice · doi:10.4158/ep09233.ra · Cited by 129
Antithyroid drug therapy: 70 years later
Burch, H. B., & Cooper, D. S. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0678 · Cited by 126
Wiersinga, W. M., Eckstein, A. K., & Žarković, M. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00066-x · Cited by 132
Thyroid dermopathy and acropachy
Fatourechi, V. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.001 · Cited by 123
THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma
Baudin, É., Habra, M. A., Deschamps, F., Cote, G. J., Dumont, F., Cabanillas, M. E., Arfi, J., Berdelou, A., Moon, B., Ghuzlan, A. A., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0113 · Cited by 122
Management of Neonates Born to Mothers With Graves’ Disease
van der Kaay, D. C. M., Wasserman, J. D., & Palmert, M. R. (2016) · PEDIATRICS · doi:10.1542/peds.2015-1878 · Cited by 117
Thyroid Autoantibodies in Pregnancy: Their Role, Regulation and Clinical Relevance
Balucan, F. S., MORSHED, S. A., & Davies, T. F. (2013) · Journal of Thyroid Research · doi:10.1155/2013/182472 · Cited by 118
Laurberg, P., & Andersen, S. L. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0135 · Cited by 115
Self-citationThe Long-Term Outcome of Treatment for Graves' Hyperthyroidism
Sjölin, G., Holmberg, M., Törring, O., Byström, K., Khamisi, S., de Laval, D., Abraham‐Nordling, M., Calissendorff, J., Lantz, M., Hallengren, B., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0085 · Cited by 112
Self-citationTörring, O., Watt, T., Sjölin, G., Byström, K., Abraham‐Nordling, M., Calissendorff, J., Cramon, P. K., Nyström, H. F., Hallengren, B., Holmberg, M., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0315 · Cited by 107
Self-citationVillagelin, D., Romaldini, J. H., dos Santos, R. B., Milkos, A. B. B. P., & Ward, L. S. (2015) · Thyroid · doi:10.1089/thy.2015.0195 · Cited by 100
Prevention of Graves’ ophthalmopathy
Bartalena, L. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.09.004 · Cited by 98
Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy
Lee, S. Y., & Pearce, E. N. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa945 · Cited by 99
Graves’ hyperthyroidism in pregnancy: a clinical review
Nguyen, C. T., Sasso, E. B., Barton, L., & Mestman, J. H. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0054-7 · Cited by 94
The Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated Orbitopathy
Bartalena, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2329 · Cited by 93
Graves’ Orbitopathy Activation after Radioactive Iodine Therapy with and without Steroid Prophylaxis
Vannucchi, G., Campi, I., Covelli, D., Dazzi, D., Currò, N., Simonetta, S., Ratiglia, R., Beck-Peccoz, P., & Salvi, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0506 · Cited by 92
Graves' Disease: Can It Be Cured?
Wiersinga, W. M. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.29 · Cited by 90
Dottore, G. R., Torregrossa, L., Caturegli, P., Ionni, I., Sframeli, A. T., Sabini, E., Menconi, F., Piaggi, P., Sellari‐Franceschini, S., Nardi, M., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.0806 · Cited by 88
Laurberg, P., Berman, D. C., Andersen, S., & Pedersen, I. B. (2011) · Thyroid · doi:10.1089/thy.2011.0039 · Cited by 87
Self-citationThyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance
Bucci, I., Giuliani, C., & Napolitano, G. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00137 · Cited by 81
Kahaly, G. J., Bartalena, L., & Hegedüs, L. (2011) · Thyroid® · doi:10.1089/thy.2011.2106.ed3 · Cited by 80
Dwivedi, S. N., Kalaria, T., & Buch, H. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208290 · Cited by 79
Optimization of current and future therapy for autoimmune diseases
Steinman, L., Merrill, J. T., McInnes, I. B., & Peakman, M. (2012) · Nature Medicine · doi:10.1038/nm.2625 · Cited by 79
Elbers, L. P. B., Mourits, M. P., & Wiersinga, W. M. (2010) · Thyroid · doi:10.1089/thy.2010.0181 · Cited by 78
The Tale of Radioiodine and Graves' Orbitopathy
Ponto, K. A., Zang, S., & Kahaly, G. J. (2010) · Thyroid · doi:10.1089/thy.2010.1640 · Cited by 77
Clinical review about TRAb assay's history
Zöphel, K., Roggenbuck, D., & Schott, M. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.05.021 · Cited by 77
Controversies in the management of Graves’ disease in children
Rivkees, S. A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0477-x · Cited by 77
Gessl, A., Lemmens‐Gruber, R., & Kautzky‐Willer, A. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_17 · Cited by 79
Bartalena, L., Chiovato, L., & Vitti, P. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0505-x · Cited by 75
Kumar, S., Schiefer, R., Coenen, M. J., & Bahn, R. S. (2009) · Thyroid · doi:10.1089/thy.2009.0278 · Cited by 75
Hyperthyroidism in the pregnant woman: Maternal and fetal aspects
Moleti, M., Mauro, M. D., Sturniolo, G., Russo, M., & Vermiglio, F. (2019) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2019.100190 · Cited by 78
van Dijk, M. M., Smits, I., Fliers, E., & Bisschop, P. H. L. T. (2018) · Thyroid · doi:10.1089/thy.2017.0413 · Cited by 73
Thyrotropin Receptor Antibodies—An Overview
Kotwal, A., & Stan, M. N. (2018) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001052 · Cited by 73
Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors
Bartalena, L., Gallo, D., Tanda, M. L., & Kahaly, G. J. (2023) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000002467 · Cited by 73
Doubleday, A. R., & Sippel, R. S. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.01 · Cited by 73
Graves' Orbitopathy: Imperfect Treatments for a Rare Disease
Bartalena, L. (2013) · European Thyroid Journal · doi:10.1159/000356042 · Cited by 70
Approach to the Pediatric Patient with Graves' Disease: When Is Definitive Therapy Warranted?
Bauer, A. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0898 · Cited by 66
Outcomes of Children with Hashitoxicosis
Wasniewska, M. G., Corrias, A., Salerno, M., Lombardo, F., Aversa, T., Mussa, A., Capalbo, D., Luca, F. D., & Valenzise, M. (2012) · Hormone Research in Paediatrics · doi:10.1159/000334640 · Cited by 63
Wpływ palenia papierosów na tarczycę — aktualizacja
Sawicka‐Gutaj, N., Gutaj, P., Sowiński, J., Wender-Ożegowska, E., Czarnywojtek, A., Brązert, J., & Ruchała, M. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0008 · Cited by 62
Diana, T., & Kahaly, G. J. (2018) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001053 · Cited by 62
Measuring TSH receptor antibody to influence treatment choices in Graves’ disease
Asha, H. S., & Abraham, P. (2017) · Clinical Endocrinology · doi:10.1111/cen.13327 · Cited by 61
Relapse following antithyroid drug therapy for Graves’ hyperthyroidism
Laurberg, P., Krejbjerg, A., & Andersen, S. L. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000088 · Cited by 60
Self-citationPreconception management of thyroid dysfunction
Okosieme, O. E., Khan, I., & Taylor, P. N. (2018) · Clinical Endocrinology · doi:10.1111/cen.13731 · Cited by 59
Benign thyroid disease in pregnancy: A state of the art review
Tingi, E., Syed, A. A., Kyriacou, A., Mastorakos, G. P., & Kyriacou, A. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.11.001 · Cited by 62
Mariani, G., Tonacchera, M., Grosso, M., Orsolini, F., Vitti, P., & Strausś, H. W. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243170 · Cited by 77
Jang, S. Y., Shin, D. Y., Lee, E. J., Lee, S. Y., & Yoon, J. S. (2013) · Eye · doi:10.1038/eye.2013.120 · Cited by 60
The Role of Thyrotrophin Receptor Antibody Assays in Graves’ Disease
Kamath, C., Adlan, M. A., & Premawardhana, L. D. K. E. (2012) · Journal of Thyroid Research · doi:10.1155/2012/525936 · Cited by 57
Léger, J., & Carel, J. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0938 · Cited by 57
Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy
Ponto, K. A., Diana, T., Binder, H., Matheis, N., Pitz, S., Pfeiffer, N., & Kahaly, G. J. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0254-2 · Cited by 56
Bartalena, L., Macchia, P. E., Marcocci, C., Salvi, M., & Vermiglio, F. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0257-z · Cited by 56
van Trotsenburg, A. S. P. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101437 · Cited by 57
Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016
Minamitani, K., Sato, H., Ohye, H., Harada, S., & Arisaka, O. (2017) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.26.29 · Cited by 54
Outcome Prediction of Treatment of Graves’ Hyperthyroidism with Antithyroid Drugs
Piantanida, E., Lai, A., Sassi, L., Gallo, D., Spreafico, E., Tanda, M. L., & Bartalena, L. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555759 · Cited by 53
The thyroid, the eyes and the gut: a possible connection
Covelli, D., & Ludgate, M. E. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0594-6 · Cited by 53
Radioiodine treatment for graves’ disease: a 10-year Australian cohort study
Fanning, E., Inder, W. J., & Mackenzie, E. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0322-7 · Cited by 53
Kobaly, K. N., & Mandel, S. J. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.002 · Cited by 53
Radioiodine therapy versus antithyroid medications for Graves' disease
Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010094.pub2 · Cited by 51
Carlé, A., Andersen, S. L., Boelaert, K., & Laurberg, P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0276 · Cited by 51
Self-citationAntithyroid Drug Therapy for Graves’ Disease and Implications for Recurrence
Liu, J., Fu, J. H., Xu, Y., & Wang, G. (2017) · International Journal of Endocrinology · doi:10.1155/2017/3813540 · Cited by 48
Samuels, S. L., LETURIA, S. M. N., & Bauer, A. J. (2017) · Clinics in Perinatology · doi:10.1016/j.clp.2017.10.001 · Cited by 47
Screening for associated autoimmune disorders in Polish patients with Addison’s disease
Fichna, M., Fichna, P., Gryczyńska, M., Walkowiak, J., Żurawek, M., & Sowiński, J. (2010) · Endocrine · doi:10.1007/s12020-010-9312-x · Cited by 47
Certain HLA alleles are associated with stress-triggered Graves’ disease and influence its course
Vita, R., Lapa, D., Trimarchi, F., Vita, G., Fallahi, P., Antonelli, A., & Benvenga, S. (2016) · Endocrine · doi:10.1007/s12020-016-0909-6 · Cited by 45
Vannucchi, G. M., Covelli, D., Campi, I., Currò, N., Dazzi, D., Rodari, M., Pepe, G., Chiti, A., Guastella, C., Lazzaroni, E., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0150 · Cited by 44
Woo, Y. J., Jang, S. Y., Lim, T. H. T., & Yoon, J. S. (2015) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2015.29.4.213 · Cited by 42
Kawkgi, O. M. E., Ross, D. S., & Stan, M. N. (2020) · Clinical Endocrinology · doi:10.1111/cen.14374 · Cited by 46
ENDOCRINOLOGY IN PREGNANCY: Pregnancy and the incidence, diagnosing and therapy of Graves’ disease
Laurberg, P., & Andersen, S. L. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0410 · Cited by 42
Self-citationTotal thyroid ablation in Graves’ orbitopathy
Menconi, F., Leo, M., Vitti, P., Marcocci, C., & Marinò, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0255-1 · Cited by 41
Hamada, N., Momotani, N., Ishikawa, N., Noh, J. Y., Okamoto, Y., Konishi, T., Ito, K., & Ito, K. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-123 · Cited by 40
Current and Future Treatments for Graves’ Disease and Graves’ Ophthalmopathy
Kotwal, A., & Stan, M. N. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0739-8134 · Cited by 41
Metadata
- Authors
- Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O.
- Affiliations
- Aalborg University Hospital (DK)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Laurberg, Peter
- ORCID
- Wallin, Göran
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01
- Volume
- 158
- Issue
- 1
- Pages
- 69-75
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2161176285
- Cited by
- 428
- References
- 36
- Citations by year
- 2026: 7 · 2025: 32 · 2024: 22 · 2023: 19 · 2022: 30 · 2021: 31 · 2020: 30 · 2019: 28 · 2018: 30 · 2017: 19 · 2016: 19 · 2015: 29 · 2014: 28 · 2013: 21 · 2012: 27
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' disease, TSH receptor antibodies, antithyroid drugs, thyroid surgery, radioiodine therapy, hyperthyroidism treatment, levothyroxine
- MeSH terms
- Adult, Autoantibodies, Graves Disease, Humans, Iodine Radioisotopes, Middle Aged, Prospective Studies, Receptors, Thyrotropin, Antithyroid Agents, Thyroidectomy, Thyroxine, Time Factors, Triiodothyronine, Autoimmunity, Treatment Outcome, Immunoglobulins, Thyroid-Stimulating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
